Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients

Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients

Chia-Ming Chang,1–3 Ming-Shun Hsieh,1–4 Tsung-Chieh Yang,3,5 Vivian Chia-Rong Hsieh,6 Jen-Huai Chiang,7 Hsien-Hao Huang,1,3 Chorng-Kuang How,1,3 Sung-Yuan Hu,8 David Hung-Tsang Yen1,3 1Department of Emergency Medicine, Taipei Veterans General Hospital, 2Institute of Occupational...

Full description

Bibliographic Details
Main Authors: Chang CM, Hsieh MS, Yang TC, Hsieh VC, Chiang JH, Huang HH, How CK, Hu SY, Yen DH
Format: Article
Language:English
Published: Dove Medical Press 2017-11-01
Series:Cancer Management and Research
Subjects:
Selective serotonin reuptake inhibitors (SSRI)
Hepatitis B virus (HBV)
Hepatocellular carcinoma (HCC)
Depression
Online Access:https://www.dovepress.com/selective-serotonin-reuptake-inhibitors-and-the-risk-of-hepatocellular-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/selective-serotonin-reuptake-inhibitors-and-the-risk-of-hepatocellular-peer-reviewed-article-CMAR

Similar Items